Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research.
Her work in animal models of type 1 diabetes established 1,25-dihydroxyvitamin D3 as an immune modulator and demonstrated the potential of Lactococcus Lactis as a carrier tool for peptides and proteins, which became the basis for a worldwide clinical trial in people with newly diagnosed type 1 diabetes.
Her research group was amongst the first to demonstrate the relevance of post-translational modifications of beta-cell peptides and proteins in autoantigen generation in murine and human type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes as well as her educational skills have made her a prominent speaker in international fora.
She has promoted shared-care, positioning of diabetes education and reimbursement of novel technologies. Prof. Mathieu is co-author of several consensus papers, including the 2018-19 ADA/EASD Consensus on glucose lowering therapies in type 2 diabetes. Prof. Mathieu leads the INNODIA project and established its Patient Advisory Committee. Prof. Mathieu is also (senior) vice-president of EASD, Chair of postgraduate education and Chair of the European Diabetes Forum.